Table 2.
Baseline Characteristics of NVAF Patients With Liver Cirrhosis Taking Apixaban, Dabigatran, and Rivaroxaban
| Apixaban (n=171) | Dabigatran (n=535) | Rivaroxaban (n=732) | P Value | |
|---|---|---|---|---|
| Age, y, mean±SD | 75.36±10.26 | 73.57±10.45 | 74.68±10.59 | 0.0722a |
| Age group | ||||
| <65, y | 11.70 | 18.32 | 17.21 | |
| 65–74, y | 33.92 | 27.85 | 25.41 | |
| 75–84, y | 36.26 | 40.19 | 41.67 | |
| >85, y | 18.13 | 13.64 | 15.71 | |
| Male sex | 55.56 | 65.98 | 61.34 | 0.0353 |
| CHA2DS2‐VASc, mean±SD | 3.98±1.57 | 3.82±1.46 | 3.90±1.57 | 0.4457a |
| HAS‐BLED, mean±SD | 3.90±1.04 | 3.82±1.46 | 3.90±3.76 | 0.1306a |
| Hypertension | 87.72 | 86.54 | 85.93 | 0.8192 |
| Diabetes mellitus | 43.86 | 46.36 | 46.86 | 0.7781 |
| Dyslipidemia | 41.52 | 40.37 | 43.58 | 0.5134 |
| Chronic kidney disease | 41.52 | 29.91 | 36.07 | 0.0085 |
| Chronic lung disease | 3.51 | 3.36 | 4.51 | 0.5577 |
| Gout | 30.41 | 28.41 | 32.65 | 0.2698 |
| Congestive heart failure | 18.71 | 21.50 | 20.22 | 0.7064 |
| Chronic ischemic heart disease | 15.79 | 11.78 | 12.84 | 0.3919 |
| PAD | 0.00 | 0.00 | 0.14 | 1.0000b |
| Stroke | 20.47 | 21.50 | 19.95 | 0.7962 |
| TIA | 2.92 | 2.06 | 3.14 | 0.4930 |
| Malignancy | 26.32 | 21.31 | 18.31 | 0.0513 |
| PCI | 7.02 | 4.30 | 5.87 | 0.0513 |
| CABG | 0.58 | 0.37 | 0.27 | 0.6838 |
| History of bleeding | 4.68 | 4.49 | 4.78 | 0.9700 |
| Use of NSAIDs | 30.99 | 24.11 | 26.91 | 0.1827 |
| Use of PPI | 19.88 | 18.13 | 19.81 | 0.7332 |
| Use of H2 blocker | 38.60 | 37.94 | 40.57 | 0.6240 |
| Use of ACEI/ARB | 5.85 | 24.67 | 14.62 | 0.0001 |
| Use of amiodarone | 32.16 | 25.05 | 30.05 | 0.0769 |
| Use of dronedarone | 2.34 | 1.50 | 2.46 | 0.4805 |
| Use of β‐blocker | 60.82 | 54.77 | 58.74 | 0.2381 |
| Use of diltiazem/verapamil | 25.15 | 25.42 | 26.23 | 0.9282 |
| Use of digoxin | 17.54 | 27.29 | 25.55 | 0.0370 |
| Use of statin | 4.09 | 10.09 | 7.24 | 0.0253 |
Data are shown as percentages except as noted. P values were calculated with the χ2 test except as noted. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; CABG, coronary artery bypass grafting; CHA2DS2‐VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65–74 years, female; HAS‐BLED, hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio (could not be determined from claims and was excluded from our scoring), age ≥65 years, and antiplatelet drug or alcohol use; NVAF, nonvalvular atrial fibrillation; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; TIA, transient ischemic attack.
ANOVA.
Fisher exact test.